Regencell Bioscience (NASDAQ:RGC) Trading Down 4.2% – Should You Sell?

Regencell Bioscience Holdings Limited (NASDAQ:RGC) shares traded down 4.2% during mid-day trading on Monday . The stock traded as low as $11.78 and last traded at $11.96. 95,263 shares were traded during mid-day trading, a decline of 99% from the average session volume of 7,994,849 shares. The stock had previously closed at $12.48.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Regencell Bioscience in a research report on Monday. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has an average rating of “Sell”.

Regencell Bioscience Stock Down 1.5%

The stock’s 50-day moving average price is $15.37.

Institutional Investors Weigh In On Regencell Bioscience

Several large investors have recently added to or reduced their stakes in RGC. Greenfield Savings Bank acquired a new stake in Regencell Bioscience during the 2nd quarter worth approximately $187,000. Y Intercept Hong Kong Ltd acquired a new position in shares of Regencell Bioscience in the second quarter worth $222,000. XTX Topco Ltd acquired a new stake in shares of Regencell Bioscience in the third quarter valued at $598,000. BNP Paribas Financial Markets acquired a new stake in shares of Regencell Bioscience in the second quarter valued at $768,000. Finally, Squarepoint Ops LLC purchased a new position in Regencell Bioscience in the second quarter valued at $1,701,000. 0.13% of the stock is owned by hedge funds and other institutional investors.

About Regencell Bioscience

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder.